Ortivus (ORTI) Q3 2025 earnings summary

Executive summary

• Net sales for Q3 2025 decreased by 13% year-over-year to SEK 16.8 million; gross margin dropped to 26% from 47%.

• EBITDA for Q3 was SEK -4.4 million, and net profit after tax was SEK -5.9 million, both declining compared to the prior year.

• For the nine months, net sales fell 8% to SEK 54.7 million, with a stable gross margin of 40%.

• A rights issue raised SEK 54.1 million, strengthening the balance sheet and enabling repayment of SEK 37 million in debt.

• The company is seeing increased market interest and demand, especially for its MobiMed 5 platform, and is expanding internationally, including into Australia.

Financial highlights

• Q3 net sales: SEK 16.8 million (down 13% year-over-year); nine-month net sales: SEK 54.7 million (down 8%).

• Q3 gross margin: 26% (down from 47%); nine-month gross margin: 40% (unchanged).

• Q3 EBITDA: SEK -4.4 million; nine-month EBITDA: SEK -10.4 million.

• Q3 net profit after tax: SEK -5.9 million; nine-month net profit after tax: SEK -14.9 million.

• Earnings per share for Q3: SEK -0.13; for nine months: SEK -0.34.

Outlook and guidance

• Positive outlook driven by increased market demand and product development pace.

• Focus on achieving sustainable profitability and positive cash flow in 2026.

• International expansion, notably into Australia, is expected to open new business opportunities.